Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, tolerability and pharmacokinetics (PKs) of multiple oral doses of GR3027 in healthy male volunteers and single and multiple doses in patients with cirrhosis. Preliminary efficacy in cirrhotic patients with evidence of covert hepatic encephalopathy (CHE). A prospective, double-blinded, randomized, placebo-controlled phase I/IIa study

Next Previous
Trial Profile

Safety, tolerability and pharmacokinetics (PKs) of multiple oral doses of GR3027 in healthy male volunteers and single and multiple doses in patients with cirrhosis. Preliminary efficacy in cirrhotic patients with evidence of covert hepatic encephalopathy (CHE). A prospective, double-blinded, randomized, placebo-controlled phase I/IIa study

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golexanolone (Primary)
  • Indications Hepatic encephalopathy
  • Focus Adverse reactions
  • Sponsors Umecrine Cognition

Most Recent Events

  • 24 Mar 2021 Results published in the Journal of Hepatology
  • 12 Feb 2020 this trial has been completed in Denmark, according to eudra record.
  • 06 Feb 2020 This trial has been completed in Hungary (Global End Date: 20 Jan 2020), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top